A transcription factor is the target of propranolol treatment in infantile hemangioma

Schrenk, Sandra; Boscolo, Elisa

doi:10.1172/jci156863

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Propranolol is now known to be effective in treating non‐cardiovascular and cardiology disorders including hypertension, arrhythmias, migraine, and anxiety 7–11 . Although propranolol has been proven to be safe and effective in treating various diseases, 12 it must be noted that propranolol has two stereoisomeric forms, 13,14 both with differing medicinal effect on patients 15,16 . These effects include the drug's ability to reach the target site in a timely and accurate manner, as well as its rate of release without unwanted spreading to other areas.…”

Section: Introductionmentioning

confidence: 99%

An enantioselective study of β‐cyclodextrin and ionic liquid‐β‐cyclodextrin towards propranolol enantiomers by molecular dynamic simulations

Ishak,

Aun,

Sidek

et al. 2024

J Comput Chem

View full text Add to dashboard Cite

In this study, the enantioselectivity of β‐cyclodextrin and its derivatives towards propranolol enantiomers are investigated by molecular dynamic (MD) simulations. β‐cyclodextrin (β‐CD) have previously been shown to be able to recognize propranolol (PRP) enantiomers. To improve upon the enantioselectivity of β‐cyclodextrin, we propose the use of an ionic‐liquid‐modified‐β‐cyclodextrin (β‐CD‐IL). β‐CD‐IL was found to be able to complex R and S propranolol enantiomers with differing binding energies. The molecular docking study reveals that the ionic liquid chain attached to the β‐CD molecule has significant interaction with propranolol. The formation of the most stable complex occurred between (S)‐β‐CD‐IL and (S)‐propranolol with an energy of −5.80 kcal/mol. This is attributed to the formation of a hydrogen bond between the oxygen of the propranolol and the hydrogen on the primary rim of the (S)‐β‐CD‐IL cavity. This interaction is not detected in other complexes. The root mean‐squared fluctuation (RMSF) value indicates that the NH group is the most flexible molecular fragment, followed by the aromatic group. Also of note, the formation of a complex between pristine β‐CD and (S)‐propranolol is the least favorable.

show abstract

Section: Introductionmentioning

confidence: 99%

An enantioselective study of β‐cyclodextrin and ionic liquid‐β‐cyclodextrin towards propranolol enantiomers by molecular dynamic simulations

Ishak,

Aun,

Sidek

et al. 2024

J Comput Chem

View full text Add to dashboard Cite

show abstract

“… 1 IHs appear shortly after birth and exhibit a unique life cycle characterized by rapid growth during the first 9–12 months, followed by slow and spontaneous regression. 2 , 3 Complications, including obstruction, dysfunction, ulceration, and disfigurement, occur in approximately 10% of patients. 4 Site-specific IHs can cause significant problems, such as organ failure, visual impairment, limited joint movement, respiratory distress, and death.…”

Section: Introductionmentioning

confidence: 99%

M2 Macrophage-Derived Exosomal lncRNA MIR4435-2HG Promotes Progression of Infantile Hemangiomas by Targeting HNRNPA1

Li,

Cao,

et al. 2023

IJN

View full text Add to dashboard Cite

Purpose Infantile hemangiomas (IHs) are commonly observed benign tumors that can cause serious complications. M2-polarized macrophages in IHs promote disease progression. In this study, we investigated the role of M2 macrophage-derived exosomal lncRNA MIR4435-2HG in IHs. Patients and Methods Exosomes derived from M2 polarized macrophages were extracted. Next, using cell co-culture or transfection, we investigated whether M2 polarized macrophage-derived exosomes (M2-exos) can transport MIR4435-2HG to regulate the proliferation, migration, invasion, and angiogenesis of hemangioma-derived endothelial cells (HemECs). RNA-seq and RNA pull-down assays were performed to identify targets and regulatory pathways of MIR4435-2HG. We explored the possible mechanisms through which MIR4435-2HG regulates the biological function of HemECs. Results M2-exos significantly enhanced the proliferation, migration, invasion, and angiogenesis of HemECs. Thus, HemECs uptake M2-exos and promote biological functions through the inclusion of MIR4435-2HG. RNA-seq and RNA pull-down experiments confirmed that MIR4435-2HG regulates of HNRNPA1 expression and directly binds to HNRNPA1, consequently affecting the NF-κB signal pathway. Conclusion MIR4435-2HG of M2-exos promotes the progression of IHs and enhances the proliferation, migration, invasion, and angiogenesis of HemECs by directly binding to HNRNPA1. This study not only reveals the mechanism of interaction between M2 macrophages and HemECs, but also provides a promising therapeutic target for IHs.

show abstract

“…Although the precise mechanism of action remains uncertain, it's believed that P acts by inhibiting vasoconstriction and angiogenesis in endothelial cells, leading to apoptosis (15). Additionally, recent studies have indicated that P hinders the differentiation of hemangioma stem cells into hemangioma endothelial cells (17). Most cases experience complete resolution, with response rates reaching up to 100% (15,18).…”

Section: Introductionmentioning

confidence: 99%

Oral topical timolol maleat or oral propranolol treatment for infantile hemangiomas: Clinical analysis of 403 patients

Terzi,

Arslantaş,

Baş

et al. 2023

Sanamed

View full text Add to dashboard Cite

Objective: Infantile hemangiomas (IH) are the most common benign vascular tumors of infancy. Propranolol (P), a nonselective beta-blocker, has been successfully used in managing IHs. Ongoing studies investigate the efficacy of the topical b-antagonist timolol maleate (TM) in IHs. The aim of this study is to assess the effects of interventions for managing infantile hemangiomas in children. Material and Methods: We retrospectively reviewed a total of 403 IH patients from March 2021 to March 2022. The patients were stratified into three groups. Patients in Group 1 were given TM at a dose of one drop topically twice a day, 0.5%. Patients in Group 2 were given P at a dose of 1 mg/kg twice a day. The patients in Group 3 did not receive any treatment, and observation was conducted solely by contacting the controls. Results: The median age of diagnosis was 5 months (range 0-60), with 57.1% of the cases being male. While TM treatment was applied to 32% of the children and P treatment was applied to 46.9% of the children, no treatment was administered in 21.1%. The most common location of hemangiomas was the face, accounting for 39.2%. Hemangiomas were observed in more than one location in 48 (12%) children. The median follow-up period for the patients was 4 months (range 0-28). Hemangiomas remained unchanged in 28.3% of all cases, shrank in 60.3%, and continued to grow in 11.4%. The primary indication for initiating TM was superficial hemangiomas and infants younger than 6 months. The leading reason for starting P significantly higher than in the other groups (p : 0.001). No statistically significant differences were observed between the groups regarding bleeding and ulceration rates (p > 0.05). Conclusion: The efficacy of propranolol in treating IH was higher than that of TM.

show abstract

A transcription factor is the target of propranolol treatment in infantile hemangioma

Cited by 6 publications

References 24 publications

An enantioselective study of β‐cyclodextrin and ionic liquid‐β‐cyclodextrin towards propranolol enantiomers by molecular dynamic simulations

An enantioselective study of β‐cyclodextrin and ionic liquid‐β‐cyclodextrin towards propranolol enantiomers by molecular dynamic simulations

M2 Macrophage-Derived Exosomal lncRNA MIR4435-2HG Promotes Progression of Infantile Hemangiomas by Targeting HNRNPA1

Oral topical timolol maleat or oral propranolol treatment for infantile hemangiomas: Clinical analysis of 403 patients

Contact Info

Product

Resources

About